AERs for OTCs
This article was originally published in The Tan Sheet
FDA is "trying to propose a rule for OTC products with FDA reporting requirements," Office of Drug Safety Division of Drug Risk Evaluation Associate Director Min Chen said at a DIA Pharmacovigilance meeting in Washington, D.C. Jan. 24. The goal is to plug the "big hole in the safety reporting game" caused by monograph OTC drugs, Chen explained. Initial development of funding is coming from some of last year's funds, she said. "Congress is behind us as far as OTC products and dietary supplements, and hopefully, this will be next year, we'll have some updates in this area"...
You may also be interested in...
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.